Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 2/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085975 | 0.78 | NPC1 (0.42) | NPC1RAB9APTPN1CYP3A4MAPT | |
| SCHEMBL6737165 | 0.77 | ALDH1A1 (0.36) | NPC1RAB9ASYKCYP3A4MAPT | |
| SCHEMBL7093467 | 0.76 | ACHE (0.48) | ACHENPC1RAB9ACYP3A4MAPT | |
| SCHEMBL15313667 | 0.76 | CA2 (0.42) | ACHENPC1RAB9APTPN1MAPT | |
| SCHEMBL6736093 | 0.75 | SELL (0.37) | ACHENPC1RAB9AMAPT | |
| SCHEMBL15313665 | 0.73 | LMNA (0.36) | NPC1RAB9AMAPT | |
| SCHEMBL27438368 | 0.72 | ACHE (0.48) | ACHENPC1RAB9ASYKCYP3A4 | |
| SCHEMBL18085976 | 0.72 | NPC1 (0.37) | NPC1RAB9AMAPT | |
| SCHEMBL14190201 | 0.71 | CYP3A4 (0.32) | SYKCYP3A4 | |
| SCHEMBL3076329 | 0.70 | ALDH1A1 (0.38) | NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | ACHE 887/4885NPC1 1887/4885RAB9A 3911/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | ACHE 837/4885NPC1 1824/4885RAB9A 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.